Blood Pressure Variability: Assessment, Predictive Value, and Potential as a Therapeutic Target

Current Hypertension Reports

Volumn 17, Issue 4, 2015, Pages 1-18

  Parati, Gianfranco ^a,b   Ochoa, Juan Eugenio ^b   Lombardi, Carolina ^b   Bilo, Grzegorz ^b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Ambulatory BP monitoring; Antihypertensive treatment; Arterial hypertension; Blood pressure; BP; Cardiovascular morbidity and mortality; Cardiovascular risk; Home BP monitoring; Short , mid , and long term BP variability

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ALBUMINURIA; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DIABETIC PATIENT; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MORBIDITY; MUSCLE SYMPATHETIC NERVE ACTIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PREDICTIVE VALUE; REGULATORY MECHANISM; REVIEW; ANIMAL; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; PROGNOSIS; RISK FACTORS;

EID: 84925034854     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-015-0537-1     Document Type: Review

References (164)

1. Parati G, Ochoa JE, Lombardi C, Bilo G. Assessment and management of blood-pressure variability. Nat Rev Cardiol. 2013;10:143–55. This review provides an in-depth description of the mechanisms of BPV, the methods currently used for BPV assessment, and the clinical relevance and prognostic importance of various types of BPV.
2. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlof B, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375(9718):895–905. This study provides evidence that in populations at high cardiovascular risk increasing values of intraindividual visit-to-visit BPV, may be prognostically more relevant than average blood pressure values.
3. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet. 2010;375(9718):938–48.
4. Parati G, Saul JP, Di Rienzo M, Mancia G. Spectral analysis of blood pressure and heart rate variability in evaluating cardiovascular regulation. A critical appraisal. Hypertension. 1995;25(6):1276–86.
5. Mancia G PG, di Rienzo M, Zanchetti A. Blood pressure variability. In: Mancia G ZA, editor. Handbook of hypertension: pathophysiology of hypertension. Amsterdam: Elsevier Science; 1997. p. 117–69.
6. Mancia G, Di Rienzo M, Parati G. Ambulatory blood pressure monitoring use in hypertension research and clinical practice. Hypertension. 1993;21(4):510–24.
7. Parati G, Stergiou G, O’Brien E, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32(7):1359–66.
8. di Rienzo M, Grassi G, Pedotti A, Mancia G. Continuous vs intermittent blood pressure measurements in estimating 24-hour average blood pressure. Hypertension. 1983;5(2):264–9. This study provides evidence that estimation of short-term BPV within the 24 hours is possible by performing non-invasive, intermittent 24h ABPM.
9. Mena L, Pintos S, Queipo NV, Aizpurua JA, Maestre G, Sulbaran T. A reliable index for the prognostic significance of blood pressure variability. J Hypertens. 2005;23(3):505–11.
10. Mancia G, Bombelli M, Facchetti R, Madotto F, Corrao G, Trevano FQ, et al. Long-term prognostic value of blood pressure variability in the general population: results of the Pressioni Arteriose Monitorate e Loro Associazioni Study. Hypertension. 2007;49(6):1265–70.
11. Bilo G, Giglio A, Styczkiewicz K, Caldara G, Maronati A, Kawecka-Jaszcz K, et al. A new method for assessing 24-h blood pressure variability after excluding the contribution of nocturnal blood pressure fall. J Hypertens. 2007;25(10):2058–66.
12. Stolarz-Skrzypek K, Thijs L, Richart T, Li Y, Hansen TW, Boggia J, et al. Blood pressure variability in relation to outcome in the International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome. Hypertens Res: Off J Jpn Soc Hypertens. 2010;33(8):757–66.
13. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45(1):142–61.
14. Mancia G, Parati G, Pomidossi G, Casadei R, Di Rienzo M, Zanchetti A. Arterial baroreflexes and blood pressure and heart rate variabilities in humans. Hypertension. 1986;8(2):147–53.
15. Conway J, Boon N, Davies C, Jones JV, Sleight P. Neural and humoral mechanisms involved in blood pressure variability. J Hypertens. 1984;2(2):203–8.
16. Parati G, Faini A, Valentini M. Blood pressure variability: its measurement and significance in hypertension. Curr Hypertens Rep. 2006;8(3):199–204.
17. Kotsis V, Stabouli S, Karafillis I, Papakatsika S, Rizos Z, Miyakis S, et al. Arterial stiffness and 24 h ambulatory blood pressure monitoring in young healthy volunteers: the early vascular ageing Aristotle University Thessaloniki Study (EVA-ARIS Study). Atherosclerosis. 2011;219(1):194–9.
18. Schillaci G, Bilo G, Pucci G, Laurent S, Macquin-Mavier I, Boutouyrie P, et al. Relationship between short-term blood pressure variability and large-artery stiffness in human hypertension: findings from 2 large databases. Hypertension. 2012;60(2):369–77.
19. Fukui M, Ushigome E, Tanaka M, Hamaguchi M, Tanaka T, Atsuta H, et al. Home blood pressure variability on one occasion is a novel factor associated with arterial stiffness in patients with type 2 diabetes. Hypertens Res 2013;36:219–25.
20. Narkiewicz K, Winnicki M, Schroeder K, Phillips BG, Kato M, Cwalina E, et al. Relationship between muscle sympathetic nerve activity and diurnal blood pressure profile. Hypertension. 2002;39(1):168–72.
21. Somers VK, Dyken ME, Mark AL, Abboud FM. Sympathetic-nerve activity during sleep in normal subjects. N Engl J Med. 1993;328(5):303–7.
22. Kario K, Pickering TG, Hoshide S, Eguchi K, Ishikawa J, Morinari M, et al. Morning blood pressure surge and hypertensive cerebrovascular disease: role of the alpha adrenergic sympathetic nervous system. Am J Hypertens. 2004;17(8):668–75.
23. Grassi G, Seravalle G, Quarti-Trevano F, Dell’Oro R, Bombelli M, Cuspidi C, et al. Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives. Hypertension. 2008;52(5):925–31.
24. Fujii T, Uzu T, Nishimura M, Takeji M, Kuroda S, Nakamura S, et al. Circadian rhythm of natriuresis is disturbed in nondipper type of essential hypertension. Am J Kidney Dis. 1999;33(1):29–35.
25. Verdecchia P, Schillaci G, Gatteschi C, Zampi I, Battistelli M, Bartoccini C, et al. Blunted nocturnal fall in blood pressure in hypertensive women with future cardiovascular morbid events. Circulation. 1993;88(3):986–92.
26. Haynes WG. Role of leptin in obesity-related hypertension. Exp Physiol. 2005;90(5):683–8.
27. Quinaglia T, Martins LC, Figueiredo VN, Santos RC, Yugar-Toledo JC, Martin JF, et al. Non-dipping pattern relates to endothelial dysfunction in patients with uncontrolled resistant hypertension. J Hum Hypertens. 2011;25(11):656–64.
28. Holt-Lunstad J, Steffen PR. Diurnal cortisol variation is associated with nocturnal blood pressure dipping. Psychosom Med. 2007;69(4):339–43.
29. Panarelli M, Terzolo M, Piovesan A, Osella G, Paccotti P, Pinna G, et al. 24-hour profiles of blood pressure and heart rate in Cushing’s syndrome. Evidence for differential control of cardiovascular variables by glucocorticoids. Annali italiani di medicina interna: organo ufficiale della Societa italiana di medicina interna. 1990;5(1):18–25.
30. Hohage H, Bruckner D, Arlt M, Buchholz B, Zidek W, Spieker C. Influence of cyclosporine A and FK506 on 24 h blood pressure monitoring in kidney transplant recipients. Clin Nephrol. 1996;45(5):342–4.
31. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens. 1987;5(1):93–8. This study showed that at nearly any level of 24h mean BP, the prevalence and severity of target organ damage was higher in subjects in whom the 24-h BP variability was higher, after adjusting for differences in mean BP levels.
32. Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-hour blood pressure variability. J Hypertens. 1993;11(10):1133–7. This longitudinal study showed that BPV at the initial screen is a significant predictor of target organ damage, in particular of left ventricular hypertrophy.
33. Mancia G, Parati G, Hennig M, Flatau B, Omboni S, Glavina F, et al. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens. 2001;19(11):1981–9.
34. Mancia G, Parati G. The role of blood pressure variability in end-organ damage. J Hypertens Suppl: Off J Int Soc Hypertens. 2003;21(6):S17–23.
35. Sega R, Corrao G, Bombelli M, Beltrame L, Facchetti R, Grassi G, et al. Blood pressure variability and organ damage in a general population: results from the PAMELA study (Pressioni Arteriose Monitorate E Loro Associazioni). Hypertension. 2002;39(2 Pt 2):710–4.
36. Tatasciore A, Renda G, Zimarino M, Soccio M, Bilo G, Parati G, et al. Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects. Hypertension. 2007;50(2):325–32.
37. Manios E, Tsagalis G, Tsivgoulis G, Barlas G, Koroboki E, Michas F, et al. Time rate of blood pressure variation is associated with impaired renal function in hypertensive patients. J Hypertens. 2009;27(11):2244–8.
38. Tatasciore A, Zimarino M, Tommasi R, Renda G, Schillaci G, Parati G, et al. Increased short-term blood pressure variability is associated with early left ventricular systolic dysfunction in newly diagnosed untreated hypertensive patients. J Hypertens. 2013;31(8):1653–61.
39. Sander D, Kukla C, Klingelhofer J, Winbeck K, Conrad B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: a 3-year follow-up study. Circulation. 2000;102(13):1536–41.
40. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med. 2002;347(11):797–805. This study showed that subjects with a non-dipping pattern of BP or with an increase in nocturnal BP have a higher rate of development and progression of microalbuminuria.
41. Kawai T, Ohishi M, Kamide K, Nakama C, Onishi M, Ito N, et al. Differences between daytime and nighttime blood pressure variability regarding systemic atherosclerotic change and renal function. Hypertens Res 2013;36:232–9.
42. Davidson MB, Hix JK, Vidt DG, Brotman DJ. Association of impaired diurnal blood pressure variation with a subsequent decline in glomerular filtration rate. Arch Intern Med. 2006;166(8):846–52.
43. Knudsen ST, Laugesen E, Hansen KW, Bek T, Mogensen CE, Poulsen PL. Ambulatory pulse pressure, decreased nocturnal blood pressure reduction and progression of nephropathy in type 2 diabetic patients. Diabetologia. 2009;52(4):698–704.
44. Dawson SL, Manktelow BN, Robinson TG, Panerai RB, Potter JF. Which parameters of beat-to-beat blood pressure and variability best predict early outcome after acute ischemic stroke? Stroke J Cereb Circ. 2000;31(2):463–8.
45. Pringle E, Phillips C, Thijs L, Davidson C, Staessen JA, de Leeuw PW, et al. Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. J Hypertens. 2003;21(12):2251–7.
46. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation. 2003;107(10):1401–6.
47. Kario K, Ishikawa J, Pickering TG, Hoshide S, Eguchi K, Morinari M, et al. Morning hypertension: the strongest independent risk factor for stroke in elderly hypertensive patients. Hypertens Res: Off J Jpn Soc Hypertens. 2006;29(8):581–7.
48. Verdecchia P, Angeli F, Gattobigio R, Rapicetta C, Reboldi G. Impact of blood pressure variability on cardiac and cerebrovascular complications in hypertension. Am J Hypertens. 2007;20(2):154–61.
49. Hansen TW, Thijs L, Li Y, Boggia J, Kikuya M, Bjorklund-Bodegard K, et al. Prognostic value of reading-to-reading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension. 2010;55(4):1049–57. This metanalysis provided evidence that an initial increase in BPV within the 24h is predictive for cardiovascular events and cardiovascular mortality independently of mean BP levels.
50. Kikuya M, Hozawa A, Ohokubo T, Tsuji I, Michimata M, Matsubara M, et al. Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. Hypertension. 2000;36(5):901–6.
51. Stolarz-Skrzypek K, Thijs L, Li Y, Hansen TW, Boggia J, Kuznetsova T, et al. Short-term blood pressure variability in relation to outcome in the International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome (IDACO). Acta Cardiol. 2011;66(6):701–6.
52. Staessen JA, Thijs L, Fagard R, O’Brien ET, Clement D, de Leeuw PW, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA. 1999;282(6):539–46.
53. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005;111(14):1777–83.
54. Kikuya M, Ohkubo T, Asayama K, Metoki H, Obara T, Saito S, et al. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama study. Hypertension. 2005;45(2):240–5.
55. Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51(1):55–61.
56. Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Bjorklund-Bodegard K, et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet. 2007;370(9594):1219–29.
57. Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA. Predictive role of the nighttime blood pressure. Hypertension. 2011;57(1):3–10. This is one of the studies that have consistently shown the superior prognostic value of nocturnal BP values over other components of 24h ABPM.
58. Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348(24):2407–15.
59. Fagard RH, Van Den Broeke C, De Cort P. Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice. J Hum Hypertens. 2005;19(10):801–7.
60. Redon J, Campos C, Narciso ML, Rodicio JL, Pascual JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension. 1998;31(2):712–8.
61. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46(1):156–61.
62. Hansen TW, Jeppesen J, Rasmussen S, Ibsen H, Torp-Pedersen C. Ambulatory blood pressure and mortality: a population-based study. Hypertension. 2005;45(4):499–504.
63. Metoki H, Ohkubo T, Kikuya M, Asayama K, Obara T, Hashimoto J, et al. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: the Ohasama study. Hypertension. 2006;47(2):149–54. This study provided evidence that subjects with a non-dipping or with “rising” pattern of BP at night are at an increased risk of CV events as compared to “dippers”.
64. Tsioufis C, Andrikou I, Thomopoulos C, Petras D, Manolis A, Stefanadis C. Comparative prognostic role of nighttime blood pressure and nondipping profile on renal outcomes. Am J Nephrol. 2011;33(3):277–88.
65. Amici A, Cicconetti P, Sagrafoli C, Baratta A, Passador P, Pecci T, et al. Exaggerated morning blood pressure surge and cardiovascular events. A 5-year longitudinal study in normotensive and well-controlled hypertensive elderly. Arch Gerontol Geriatr. 2009;49(2):e105–9.
66. Verdecchia P, Angeli F, Mazzotta G, Garofoli M, Ramundo E, Gentile G, et al. Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications. Hypertension. 2012;60(1):34–42. This study showed that a blunted nocturnal BP dipping but not an increased morning BP surge is associated with an increased risk of CV outcomes, the risk of CV events being higher in patients with a blunted pre-awakening BP surge (associated with reduced or absent night-time BP dipping).
67. Xie HH, Miao CY, Jiang YY, Su DF. Synergism of atenolol and nitrendipine on hemodynamic amelioration and organ protection in hypertensive rats. J Hypertens. 2005;23(1):193–201.
68. Xie HH, Shen FM, Xu LP, Han P, Miao CY, Su DF. Reduction of blood pressure variability by combination therapy in spontaneously hypertensive rats. J Hypertens. 2007;25(11):2334–44.
69. Liu JG, Xu LP, Chu ZX, Miao CY, Su DF. Contribution of blood pressure variability to the effect of nitrendipine on end-organ damage in spontaneously hypertensive rats. J Hypertens. 2003;21(10):1961–7.
70. Han P, Shen FM, Xie HH, Chen YY, Miao CY, Mehta JL, et al. The combination of atenolol and amlodipine is better than their monotherapy for preventing end-organ damage in different types of hypertension in rats. J Cell Mol Med. 2009;13(4):726–34.
71. Zanchetti A. Wars, war games, and dead bodies on the battlefield: variations on the theme of blood pressure variability. Stroke J Cereb Circ. 2011;42(10):2722–4.
72. Ferrari A, Buccino N, Di Rienzo M, Pedotti A, Mancia G, Zanchetti A. Labetalol and 24-hour monitoring of arterial blood pressure in hypertensive patients. J Cardiovasc Pharmacol. 1981;3 Suppl 1:S42–52.
73. Mancia G, Ferrari A, Gregorini L, Parati G, Pomidossi G, Grassi G, et al. Evaluation of a slow-release clonidine preparation by direct continuous blood pressure recording in essential hypertensive patients. J Cardiovasc Pharmacol. 1981;3(6):1193–202.
74. Mancia G, Ferrari A, Pomidossi G, Parati G, Bertinieri G, Grassi G, et al. Twenty-four-hour blood pressure profile and blood pressure variability in untreated hypertension and during antihypertensive treatment by once-a-day nadolol. Am Heart J. 1984;108(4 Pt 2):1078–83.
75. Pomidossi G, Parati G, Motolese M, Mancia G, Zanchetti A. Hemodynamic effects of once a day administration of combined chlorthalidone and metoprolol slow-release in essential hypertension. Int J Clin Pharmacol Ther Toxicol. 1984;22(12):665–71.
76. Pomidossi G, Parati G, Malaspina D, Camesasca C, Motolese M, Zanchetti A, et al. Antihypertensive effect of a new formulation of slow release oxprenolol in essential hypertension. J Cardiovasc Pharmacol. 1987;10(5):593–8.
77. Parati G, Pomidossi G, Casadei R, Ravogli A, Trazzi S, Mutti E, et al. 24-h ambulatory non-invasive blood pressure monitoring in the assessment of the antihypertensive action of celiprolol. J Int Med Res. 1988;16 Suppl 1:52A–61A.
78. Mancia G, De Cesaris R, Fogari R, Lattuada S, Montemurro G, Palombo C, et al. Evaluation of the antihypertensive effect of once-a-day trandolapril by 24-hour ambulatory blood pressure monitoring. The Italian Trandolapril Study Group. Am J Cardiol. 1992;70(12):60D–6D.
79. Mancia G, Omboni S, Ravogli A, Parati G, Zanchetti A. Ambulatory blood pressure monitoring in the evaluation of antihypertensive treatment: additional information from a large data base. Blood Press. 1995;4(3):148–56.
80. Parati G, Mutti E, Frattola A, Castiglioni P, di Rienzo M, Mancia G. Beta-adrenergic blocking treatment and 24-hour baroreflex sensitivity in essential hypertensive patients. Hypertension. 1994;23(6 Pt 2):992–6.
81. Frattola A, Parati G, Castiglioni P, Paleari F, Ulian L, Rovaris G, et al. Lacidipine and blood pressure variability in diabetic hypertensive patients. Hypertension. 2000;36(4):622–8.
82. Zhang Y, Agnoletti D, Safar ME, Blacher J. Effect of antihypertensive agents on blood pressure variability: the Natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study. Hypertension. 2011;58(2):155–60.
83. Levi-Marpillat N, Macquin-Mavier I, Tropeano AI, Parati G, Maison P. Antihypertensive drug classes have different effects on short-term blood pressure variability in essential hypertension. Hypertens Res: Off J Jpn Soc Hypertens. 2014;37(6):585–90. This study showed that subjects receiving either CCBs or diuretics, alone or in addition to other drugs, had significantly lower SD of 24-h SBP compared with those receiving angiotensin-converting enzyme inhibitors, angiotensin receptor blockers or beta-blockers alone or in combination.
84. Lemmer B, Nold G, Behne S, Kaiser R. Chronopharmacokinetics and cardiovascular effects of nifedipine. Chronobiol Int. 1991;8(6):485–94.
85. Palatini P, Racioppa A, Raule G, Zaninotto M, Penzo M, Pessina AC. Effect of timing of administration on the plasma ACE inhibitory activity and the antihypertensive effect of quinapril. Clin Pharmacol Ther. 1992;52(4):378–83.
86. White WB, Anders RJ, MacIntyre JM, Black HR, Sica DA. Nocturnal dosing of a novel delivery system of verapamil for systemic hypertension. Verapamil study group. Am J Cardiol. 1995;76(5):375–80.
87. Panza JA, Epstein SE, Quyyumi AA. Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. N Engl J Med. 1991;325(14):986–90.
88. Hermida RC, Calvo C, Ayala DE, Dominguez MJ, Covelo M, Fernandez JR, et al. Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension. 2003;42(3):283–90.
89. Lipicky RJ. Trough: peak ratio: the rationale behind the United States Food and Drug Administration recommendations. J Hypertens Suppl: Off J Int Soc Hypertens. 1994;12(8):S17–8. discussion S8-9.
90. Omboni S, Parati G, Zanchetti A, Mancia G. Calculation of trough:peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects. J Hypertens. 1995;13(10):1105–12.
91. Zannad F, Radauceanu A, Parati G. Trough-to-peak ratio, smoothness index and morning-to-evening ratio: why, which and when? J Hypertens. 2003;21(5):851–4.
92. Meredith PA, Elliott HL. FDA guidelines on trough: peak ratios in the evaluation of antihypertensive agents. United States Food and Drug Administration. J Cardiovasc Pharmacol. 1994;23 Suppl 5:S26–30.
93. Parati G, Omboni S, Rizzoni D, Agabiti-Rosei E, Mancia G. The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens. 1998;16(11):1685–91.
94. Rizzoni D, Muiesan ML, Salvetti M, Castellano M, Bettoni G, Monteduro C, et al. The smoothness index, but not the trough-to-peak ratio predicts changes in carotid artery wall thickness during antihypertensive treatment. J Hypertens. 2001;19(4):703–11.
95. Parati G, Schumacher H, Bilo G, Mancia G. Evaluating 24-h antihypertensive efficacy by the smoothness index: a meta-analysis of an ambulatory blood pressure monitoring database. J Hypertens. 2010;28(11):2177–83.
96. Mancia G, Ferrari A, Gregorini L, Parati G, Pomidossi G, Bertinieri G, et al. Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res. 1983;53(1):96–104.
97. Parati G, Dolan E, Ley L, Schumacher H. Impact of antihypertensive combination and monotreatments on blood pressure variability: assessment by old and new indices. Data from a large ambulatory blood pressure monitoring database. J Hypertens. 2014;32(6):1326–33. This study showed that combination treatment is associated with a smoother BP reduction over 24 h and with a more favorable balance between mean 24-h BP reduction and the degree of BP variability on treatment, also showing a similar agreement between smoothness index and TOVI for assessment of antihypertensive treatments.
98. Parati G, Schumacher H. Blood pressure variability over 24 h: prognostic implications and treatment perspectives. An assessment using the smoothness index with telmisartan-amlodipine monotherapy and combination. Hypertens Res: Off J Jpn Soc Hypertens. 2014;37(3):187–93.
99. Murakami S, Otsuka K, Kubo Y, Shinagawa M, Matsuoka O, Yamanaka T, et al. Weekly variation of home and ambulatory blood pressure and relation between arterial stiffness and blood pressure measurements in community-dwelling hypertensives. Clin Exp Hypertens. 2005;27:231–9.
100. Schutte R, Thijs L, Liu YP, Asayama K, Jin Y, Odili A, et al. Within-subject blood pressure level—not variability—predicts fatal and nonfatal outcomes in a general population. Hypertension. 2012;60(5):1138–47.
101. Ishikura K, Obara T, Kato T, Kikuya M, Shibamiya T, Shinki T, et al. Associations between day-by-day variability in blood pressure measured at home and antihypertensive drugs: the J-HOME-Morning study. Clin Exp Hypertens. 2012;34(4):297–304.
102. Johansson JK, Niiranen TJ, Puukka PJ, Jula AM. Factors affecting the variability of home-measured blood pressure and heart rate: the Finn-home study. J Hypertens. 2010;28(9):1836–45.
103. Kato T, Kikuya M, Ohkubo T, Satoh M, Hara A, Obara T, et al. Factors associated with day-by-day variability of self-measured blood pressure at home: the Ohasama study. Am J Hypertens. 2010;23(9):980–6.
104. Imai Y, Nishiyama A, Sekino M, Aihara A, Kikuya M, Ohkubo T, et al. Characteristics of blood pressure measured at home in the morning and in the evening: the Ohasama study. J Hypertens. 1999;17(7):889–98.
105. Okada H, Fukui M, Tanaka M, Inada S, Mineoka Y, Nakanishi N, et al. Visit-to-visit variability in systolic blood pressure is correlated with diabetic nephropathy and atherosclerosis in patients with type 2 diabetes. Atherosclerosis. 2012;220(1):155–9.
106. Nagai M, Hoshide S, Ishikawa J, Shimada K, Kario K. Visit-to-visit blood pressure variations: new independent determinants for carotid artery measures in the elderly at high risk of cardiovascular disease. J Am Soc Hypertens: JASH. 2011;5(3):184–92.
107. Asayama K, Kikuya M, Schutte R, Thijs L, Hosaka M, Satoh M, et al. Home blood pressure variability as cardiovascular risk factor in the population of Ohasama. Hypertension. 2013;61(1):61–9.
108. Okada T, Nakao T, Matsumoto H, Nagaoka Y, Tomaru R, Iwasawa H, et al. [Day-by-day variability of home blood pressure in patients with chronic kidney disease]. Nihon Jinzo Gakkai shi. 2008;50(5):588–96.
109. Kawabe H, Kanda T, Hirose H, Saito I. Variability of home blood pressure measurements between first and second measurements on one occasion, and factors related to variability. Clin Exp Hypertens. 2012;34(4):237–42.
110. Johansson JK, Kronholm E, Jula AM. Variability in home-measured blood pressure and heart rate: associations with self-reported insomnia and sleep duration. J Hypertens. 2011;29(10):1897–905.
111. Cacciolati C, Tzourio C, Hanon O. Blood pressure variability in elderly persons with white-coat and masked hypertension compared to those with normotension and sustained hypertension. Am J Hypertens. 2013;26(3):367–72.
112. Matsui Y, Ishikawa J, Eguchi K, Shibasaki S, Shimada K, Kario K. Maximum value of home blood pressure: a novel indicator of target organ damage in hypertension. Hypertension. 2011;57(6):1087–93. This study provided evidence that an increased day-by-day BPV independently of average home BP levels, is a predictor of development, establishment and evolution of cardiac, vascular and renal organ damage.
113. Ushigome E, Fukui M, Hamaguchi M, Senmaru T, Sakabe K, Tanaka M, et al. The coefficient variation of home blood pressure is a novel factor associated with macroalbuminuria in type 2 diabetes mellitus. Hypertens Res: Off J Jpn Soc Hypertens. 2011;34(12):1271–5.
114. Hoshide S, Yano Y, Shimizu M, Eguchi K, Ishikawa J, Kario K. Is home blood pressure variability itself an interventional target beyond lowering mean home blood pressure during anti-hypertensive treatment? Hypertens Res: Off J Jpn Soc Hypertens. 2012;35(8):862–6.
115. Nishimura M, Kato Y, Tanaka T, Todo R, Tone A, Yamada K, et al. Significance of estimating the glomerular filtration rate for the management of hypertension in type 2 diabetes with microalbuminuria. Hypertens Res: Off J Jpn Soc Hypertens. 2013;36(8):705–10.
116. Okada T, Matsumoto H, Nagaoka Y, Nakao T. Association of home blood pressure variability with progression of chronic kidney disease. Blood Press Monit. 2012;17(1):1–7.
117. Kikuya M, Ohkubo T, Metoki H, Asayama K, Hara A, Obara T, et al. Day-by-day variability of blood pressure and heart rate at home as a novel predictor of prognosis: the Ohasama study. Hypertension. 2008;52(6):1045–50. This study provided evidence that increasing values of variability in systolic HBP are associated with a higher risk of the composite end-point of cardiac and stroke mortality.
118. Hashimoto T, Kikuya M, Ohkubo T, Satoh M, Metoki H, Inoue R, et al. Home blood pressure level, blood pressure variability, smoking, and stroke risk in Japanese men: the Ohasama study. Am J Hypertens. 2012;25(8):883–91.
119. Johansson JK, Niiranen TJ, Puukka PJ, Jula AM. Prognostic value of the variability in home-measured blood pressure and heart rate: the Finn-Home Study. Hypertension. 2012;59(2):212–8. This study indicated that increasing variability in systolic and diastolic HBP is associated with a higher risk of cardiovascular events after 7.8 years of follow-up, which remained significant even after adjusting for age and average HBP levels, thus supporting the additive value of HBP variability in predicting CV prognosis.
120. Matsui Y, O’Rourke MF, Hoshide S, Ishikawa J, Shimada K, Kario K. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study. Hypertension. 2012;59(6):1132–8.
121. Ushigome E, Fukui M, Hamaguchi M, Tanaka T, Atsuta H, Ohnishi M, et al. Beneficial effect of calcium channel blockers on home blood pressure variability in the morning in patients with type 2 diabetes. J Diab Investig. 2013;4(4):399–404.
122. Muntner P, Joyce C, Levitan EB, Holt E, Shimbo D, Webber LS, et al. Reproducibility of visit-to-visit variability of blood pressure measured as part of routine clinical care. J Hypertens. 2011;29(12):2332–8.
123. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105–87.
124. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–52.
125. Benvenuto LJ, Krakoff LR. Morbidity and mortality of orthostatic hypotension: implications for management of cardiovascular disease. Am J Hypertens. 2011;24(2):135–44.
126. Whitworth JA, World Health Organization, ISoHWG. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21(11):1983–92.
127. Imai Y, Otsuka K, Kawano Y, Shimada K, Hayashi H, Tochikubo O, et al. Japanese Society of Hypertension (JSH) guidelines for self-monitoring of blood pressure at home. Hypertens Res: Off J Jpn Soc Hypertens. 2003;26(10):771–82.
128. Parati G, Bilo G. Calcium antagonist added to angiotensin receptor blocker: a recipe for reducing blood pressure variability?: evidence from day-by-day home blood pressure monitoring. Hypertension. 2012;59(6):1091–3.
129. Muntner P, Levitan EB, Joyce C, Holt E, Mann D, Oparil S, et al. Association between antihypertensive medication adherence and visit-to-visit variability of blood pressure. J Clin Hypertens (Greenwich). 2013;15(2):112–7.
130. Nagai M, Hoshide S, Nishikawa M, Shimada K, Kario K. Sleep duration and insomnia in the elderly: associations with blood pressure variability and carotid artery remodeling. Am J Hypertens. 2013;26(8):981–9.
131. Muntner P, Shimbo D, Tonelli M, Reynolds K, Arnett DK, Oparil S. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension. 2011;57(2):160–6.
132. Sega R, Cesana G, Bombelli M, Grassi G, Stella ML, Zanchetti A, et al. Seasonal variations in home and ambulatory blood pressure in the PAMELA population. Pressione Arteriose Monitorate E Loro Associazioni. J Hypertens. 1998;16(11):1585–92.
133. Modesti PA, Morabito M, Bertolozzi I, Massetti L, Panci G, Lumachi C, et al. Weather-related changes in 24-hour blood pressure profile: effects of age and implications for hypertension management. Hypertension. 2006;47(2):155–61.
134. Masugata H, Senda S, Murao K, Inukai M, Hosomi N, Iwado Y, et al. Visit-to-visit variability in blood pressure over a 1-year period is a marker of left ventricular diastolic dysfunction in treated hypertensive patients. Hypertens Res: Off J Jpn Soc Hypertens. 2011;34(7):846–50.
135. Shimbo D, Shea S, McClelland RL, Viera AJ, Mann D, Newman J, et al. Associations of aortic distensibility and arterial elasticity with long-term visit-to-visit blood pressure variability: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Hypertens. 2013;26(7):896–902.
136. Kilpatrick ES, Rigby AS, Atkin SL. The role of blood pressure variability in the development of nephropathy in type 1 diabetes. Diabetes Care. 2010;33(11):2442–7. This study indicated that increasing values of visit-to-visit BPV are associated with development of micro and macro albuminuria.
137. Kawai T, Ohishi M, Kamide K, Onishi M, Takeya Y, Tatara Y, et al. The impact of visit-to-visit variability in blood pressure on renal function. Hypertens Res: Off J Jpn Soc Hypertens. 2012;35(2):239–43.
138. Yokota K, Fukuda M, Matsui Y, Hoshide S, Shimada K, Kario K. Impact of visit-to-visit variability of blood pressure on deterioration of renal function in patients with non-diabetic chronic kidney disease. Hypertens Res 2013;36:151–7.
139. Brickman AM, Reitz C, Luchsinger JA, Manly JJ, Schupf N, Muraskin J, et al. Long-term blood pressure fluctuation and cerebrovascular disease in an elderly cohort. Arch Neurol. 2010;67(5):564–9.
140. Havlik RJ, Foley DJ, Sayer B, Masaki K, White L, Launer LJ. Variability in midlife systolic blood pressure is related to late-life brain white matter lesions: the Honolulu-Asia Aging study. Stroke J Cereb Circ. 2002;33(1):26–30.
141. Liu W, Liu R, Sun W, Peng Q, Zhang W, Xu E, et al. Different impacts of blood pressure variability on the progression of cerebral microbleeds and white matter lesions. Stroke J Cereb Circ. 2012;43(11):2916–22.
142. Diaz KM, Veerabhadrappa P, Kashem MA, Feairheller DL, Sturgeon KM, Williamson ST, et al. Relationship of visit-to-visit and ambulatory blood pressure variability to vascular function in African Americans. Hypertens Res: Off J Jpn Soc Hypertens. 2012;35(1):55–61.
143. Nagai M, Hoshide S, Ishikawa J, Shimada K, Kario K. Visit-to-visit blood pressure variations: new independent determinants for cognitive function in the elderly at high risk of cardiovascular disease. J Hypertens. 2012;30(8):1556–63.
144. Okada H, Fukui M, Tanaka M, Matsumoto S, Mineoka Y, Nakanishi N, et al. Visit-to-visit blood pressure variability is a novel risk factor for the development and progression of diabetic nephropathy in patients with type 2 diabetes. Diabetes Care. 2013;36(7):1908–12. This study consistently showed that visit-to-visit BPV in SBP is associated with an increased risk of progression of diabetic nephropathy or development of albuminuria in patients with type 2 diabetes, over and above the contribution provided by increased average BP levels.
145. Noshad S, Mousavizadeh M, Mozafari M, Nakhjavani M, Esteghamati A. Visit-to-visit blood pressure variability is related to albuminuria variability and progression in patients with type 2 diabetes. J Hum Hypertens. 2013;28:37–43.
146. Ruggenenti P, Porrini E, Motterlini N, Perna A, Ilieva AP, Iliev IP, et al. Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. J Am Soc Nephrol: JASN. 2012;23(10):1717–24.
147. Hallan SI, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth SR. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol: JASN. 2009;20(5):1069–77.
148. Parati G, Liu X, Ochoa JE. Clinical relevance of visit-to-visit blood pressure variability: impact on renal outcomes. J Hum Hypertens. 2014;28(7):403–9.
149. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke J Cereb Circ. 2003;34(5):1126–9.
150. Mancia G, Messerli F, Bakris G, Zhou Q, Champion A, Pepine CJ. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension. 2007;50(2):299–305. This study, conducted in a population of treated hypertensives at high cardiovascular risk showed a steep reduction in the incidence of fatal and non fatal CV events, but in particular of stroke, as the percentage of on-treatment visits with BP controlled increased throughout the treatment period independently of the mean office BP control achieved.
151. Hata Y, Kimura Y, Muratani H, Fukiyama K, Kawano Y, Ashida T, et al. Office blood pressure variability as a predictor of brain infarction in elderly hypertensive patients. Hypertens Res: Off J Jpn Soc Hypertens. 2000;23(6):553–60.
152. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlof B, et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9(5):469–80. This metanalysis provided evidence that increasing values of intra-individual visit-to-visit variability in on-treatment office or ambulatory BP values is predictive of cerebrovascular and coronary fatal and non-fatal events independently of mean office or ambulatory BP values.
153. Eguchi K, Hoshide S, Schwartz JE, Shimada K, Kario K. Visit-to-visit and ambulatory blood pressure variability as predictors of incident cardiovascular events in patients with hypertension. Am J Hypertens. 2012;25(9):962–8.
154. Hata Y, Muratani H, Kimura Y, Fukiyama K, Kawano Y, Ashida T, et al. Office blood pressure variability as a predictor of acute myocardial infarction in elderly patients receiving antihypertensive therapy. J Hum Hypertens. 2002;16(2):141–6.
155. Hsieh YT, Tu ST, Cho TJ, Chang SJ, Chen JF, Hsieh MC. Visit-to-visit variability in blood pressure strongly predicts all-cause mortality in patients with type 2 diabetes: a 5.5-year prospective analysis. Eur J Clin Invest. 2012;42(3):245–53.
156. Shimbo D, Newman JD, Aragaki AK, LaMonte MJ, Bavry AA, Allison M, et al. Association between annual visit-to-visit blood pressure variability and stroke in postmenopausal women: data from the Women’s Health Initiative. Hypertension. 2012;60(3):625–30.
157. Di Iorio B, Pota A, Sirico ML, Torraca S, Di Micco L, Rubino R, et al. Blood pressure variability and outcomes in chronic kidney disease. Nephrol Dial Transplant. 2012;27(12):4404–10.
158. Rossignol P, Cridlig J, Lehert P, Kessler M, Zannad F. Visit-to-visit blood pressure variability is a strong predictor of cardiovascular events in hemodialysis: insights from FOSIDIAL. Hypertension. 2012;60(2):339–46.
159. Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability in the European Lacidipine Study on Atherosclerosis: methodological aspects and effects of antihypertensive treatment. J Hypertens. 2012;30(6):1241–51.
160. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335(8693):827–38.
161. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527–35. This Meta analysis supported the prevailing role of mean BP reduction in achieving cardiovascular protection.
162. Wang JG, Yan P, Jeffers BW. Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials. J Am Soc Hypertens: JASH. 2014;8(5):340–9.
163. Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability, carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on Atherosclerosis. Circulation. 2012;126(5):569–78.
164. Parati G, Liu X, Ochoa JE, Bilo G. Prognostic relevance of blood pressure variability: role of long-term and very long-term blood pressure changes. Hypertension. 2013;62(4):682–4.